zimmer biomet is the world’s most trusted brand for personalized bone and joint healthcare solutions. we help people discover and achieve exceptional outcomes. as a leading innovator in musculoskeletal healthcare, we offer a complete portfolio of products for joint reconstruction, bone and skeletal repair, sports medicine, spine, and dental reconstruction. every day, we focus on improving musculoskeletal healthcare. it’s all we do. it’s all we’ve ever done. for nearly 90 years, zimmer biomet has helped people progress beyond their pain and limitations. because it’s not just what we make, it’s what we make possible. zimmer biomet serves healthcare professionals and their patients globally. our worldwide headquarters is in warsaw, indiana, usa.
Company profile
Ticker
ZBH
Exchange
Website
CEO
Bryan Hanson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign • RTI Surgical ...
Former names
ZIMMER HOLDINGS INC
SEC CIK
Corporate docs
Subsidiaries
A&E Advanced Closure Systems, LLC • A&E Medical Corp. • Alto Development Corp. • Avitus Orthopaedics, Inc. • Biomet Biologics, LLC • Biomet CV Holdings, LLC • Biomet Fair Lawn LLC • Biomet International, Inc. • Biomet Leasing, Inc. • Biomet Manufacturing, LLC ...
IRS number
134151777
ZBH stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEF 14A
Definitive proxy
27 Mar 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results
8 Feb 24
8-K
Zimmer Biomet Announces Appointment of
5 Jan 24
8-K
Entry into a Material Definitive Agreement
1 Dec 23
424B5
Prospectus supplement for primary offering
30 Nov 23
FWP
Free writing prospectus
28 Nov 23
424B5
Prospectus supplement for primary offering
28 Nov 23
Transcripts
ZBH
Earnings call transcript
2023 Q4
8 Feb 24
ZBH
Earnings call transcript
2023 Q3
7 Nov 23
ZBH
Earnings call transcript
2023 Q2
1 Aug 23
ZBH
Earnings call transcript
2023 Q1
2 May 23
ZBH
Earnings call transcript
2022 Q4
3 Feb 23
ZBH
Earnings call transcript
2022 Q3
2 Nov 22
ZBH
Earnings call transcript
2022 Q2
2 Aug 22
ZBH
Earnings call transcript
2022 Q1
3 May 22
ZBH
Earnings call transcript
2021 Q4
7 Feb 22
ZBH
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 292.10 mm | 292.10 mm | 292.10 mm | 292.10 mm | 292.10 mm | 292.10 mm |
Cash burn (monthly) | 9.23 mm | 21.11 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 55.01 mm | 125.77 mm | n/a | n/a | n/a | n/a |
Cash remaining | 237.09 mm | 166.33 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 25.7 | 7.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
67.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 819 |
Opened positions | 95 |
Closed positions | 259 |
Increased positions | 229 |
Reduced positions | 328 |
13F shares | Current |
---|---|
Total value | 14.47 tn |
Total shares | 138.76 mm |
Total puts | 151.20 k |
Total calls | 133.90 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 23.86 mm | $2.90 tn |
Dodge & Cox | 11.47 mm | $1.40 tn |
T. Rowe Price | 9.43 mm | $1.15 bn |
STT State Street | 9.31 mm | $1.14 tn |
IVZ Invesco | 6.21 mm | $755.21 bn |
American Century Companies | 5.93 mm | $721.96 bn |
Primecap Management | 5.09 mm | $619.04 bn |
JPM JPMorgan Chase & Co. | 3.83 mm | $465.85 bn |
Victory Capital Management | 3.20 mm | $389.36 bn |
Van Eck Associates | 2.84 mm | $345.45 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Lori Winkler | Common Stock | Payment of exercise | Dispose F | No | No | 125.82 | 428 | 53.85 k | 2,779 |
6 Mar 24 | Lori Winkler | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,757 | 0.00 | 3,207 |
6 Mar 24 | Lori Winkler | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,757 | 0.00 | 3,513 |
6 Mar 24 | Zuilen Wilfred Van | Common Stock | Payment of exercise | Dispose F | No | No | 125.82 | 260 | 32.71 k | 7,167 |
6 Mar 24 | Zuilen Wilfred Van | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,163 | 0.00 | 7,427 |
6 Mar 24 | Zuilen Wilfred Van | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,163 | 0.00 | 4,323 |
6 Mar 24 | Upadhyay Suketu | Common Stock | Payment of exercise | Dispose F | No | No | 125.82 | 1,919 | 241.45 k | 20,764 |
6 Mar 24 | Upadhyay Suketu | Common Stock | Option exercise | Acquire M | No | No | 0 | 4,561 | 0.00 | 22,683 |
6 Mar 24 | Upadhyay Suketu | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,561 | 0.00 | 9,119 |
6 Mar 24 | Ivan Tornos | Common Stock | Payment of exercise | Dispose F | No | No | 125.82 | 5,642 | 709.88 k | 26,753 |
News
Canaccord Genuity Reiterates Hold on Zimmer Biomet Holdings, Maintains $130 Price Target
23 Feb 24
Zimmer Biomet Receives FDA Clearance For ROSA Shoulder System
22 Feb 24
Truist Securities Maintains Hold on Zimmer Biomet Holdings, Raises Price Target to $135-Report released on 8th February 2024
9 Feb 24
JP Morgan Maintains Neutral on Zimmer Biomet Holdings, Raises Price Target to $125
9 Feb 24
What 7 Analyst Ratings Have To Say About Zimmer Biomet Holdings
9 Feb 24
Press releases
NeuroOnes's Innovative Electrode Brain Monitoring Seeks To Provide Insights Into Neurological Disorders
28 Mar 24
Zimmer Biomet Receives FDA Clearance for ROSA® Shoulder System - the World's First Robotic Assistant for Shoulder Replacement Surgery
22 Feb 24
Zimmer Biomet Signs Global Health Equity Network's Zero Health Gaps Pledge and Expands Longstanding Commitment to Advancing Health Equity
12 Feb 24
Zimmer Biomet Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting
12 Feb 24
4 Nanocap Stocks Under .10 Poised To Pop
12 Feb 24